Remon: n=174, used Inivata's service, 50% of mutations <1% mutant allel frequency. 17% of pts 'rescued' since now actionable Rx #MAPonco1
6:24am September 24th 2016 via Hootsuite
Remon: 25% of pts have no molecular profile. '16 Lancet https://t.co/gHSXy6S0e3 #MAPonco16
6:21am September 24th 2016 via Hootsuite
Jordi Remon (Gustave Roussey / Inivata) New Applications for ctDNA #MAPonco16
6:20am September 24th 2016 via Hootsuite
Bardelli: Clinical trial called CHRONOS, funded and enrollment open. Section on RAS prevalence, and concomitant EGFR #MAPonco16
6:12am September 24th 2016 via Hootsuite
Bardelli: 'These are disappointing stories' - the heterogeneity of primary tumors; acquiring resistance. Thus: target cancer evol #MAPonco16
6:05am September 24th 2016 via Hootsuite
Bardelli: HERACLES trial on HER2 in mCRC in recent Lancet Oncol https://t.co/lgr2xGPjmq #MAPonco16
6:01am September 24th 2016 via Hootsuite
Bardelli: ALK, MET, HER2, EGFR, TRKA, Wnt1, RSPO - and all the drugs that target. HER2 in CRC in PDX, dual-blockade #MAPonco16
5:59am September 24th 2016 via Hootsuite
Bardelli: 10y ago, there were a lot of markers, but nothing making it to the clinic. Now a lot of actionable targets #MAPonco16
5:58am September 24th 2016 via Hootsuite
Bardelli: Progression cartoon of CRC - early hyperproliferation can be detected. (progress to adenoma, to polyps, to displasia #MAPonco16
5:56am September 24th 2016 via Hootsuite
Alberto Bardelli (IRCC Univ Torino, Italy) Cancer evolution as a therapeutic target #MAPonco16
5:55am September 24th 2016 via Hootsuite
Turner: One challenge - differentiate 'normal' clonal expansions from early-stage cancer. #MAPonco16
5:54am September 24th 2016 via Hootsuite
Turner: Looking in blood - TP53 found '16 PNAS https://t.co/RBz7KvxNng Old test '06 NEJM https://t.co/FCC7G32sXy Not useful #MAPonco16
5:53am September 24th 2016 via Hootsuite
Turner: #MAPonco16 Shows data from normal skin mutations '15 Science https://t.co/HqL4Jj9nXt 'you find them all over your skin'
5:50am September 24th 2016 via Hootsuite
RT @jsoriamd: #MAPonco16 Turner warns against limitations related to cDNA for K screening: multiple mutations exist outside of K https://t.…
5:49am September 24th 2016 via Twitter Web Client
Turner: And by age: by 65y, 10% had clonal hematopoesis, with much higher risk of heme cancers. Showed survival curves #MAPonco16
5:49am September 24th 2016 via Hootsuite
Turner: These mutations were DNMT3A, and along list of known drivers. Looked across time and found >3 somatic muts #MAPonco16
5:48am September 24th 2016 via Hootsuite
Turner: Challenges to detecting cancer - 12K WES in '14 NEJM https://t.co/5BhjxlY3or Found a bump at the 12%-14% Allele fx #MAPonco16
5:47am September 24th 2016 via Hootsuite
Turner: Fig from '16 Nature Biotech https://t.co/v6Cc1aNPNu with graphical demonstration of reduction of error. 0.01% sens #MAPonco16
5:45am September 24th 2016 via Hootsuite
Turner: Shows illus from '14 Nature Protocols https://t.co/TsjA3ptwjj about how molecular barcoding can reduce seq errors #MAPonco16
5:44am September 24th 2016 via Hootsuite
Turner: Ovarian (S-IV), follicular lymphoma, Hodgkins lymphoma. Clearly not early enough. Fig from paper on how it matched plasma #MAPonco16
5:42am September 24th 2016 via Hootsuite
Turner: Shows this '15 JAMA Oncol https://t.co/XzXwAaZuPG via NIPT detecting cancers - 3 found out of 4,000 NIPT #MAPonco16
5:41am September 24th 2016 via Hootsuite
Turner: Starts with figure from this '14 STM ref https://t.co/Iqp0L4cb3K Theoretically: can be detected prior to symptoms #MAPonco16
5:40am September 24th 2016 via Hootsuite
Turner: (standing in for a GRAIL speaker, continuing on the theme of early detection) #MAPonco16
5:38am September 24th 2016 via Hootsuite
Turner: Model - w/adjuvant, tumor is more homogeneous, no ER mutant clone present. #MAPonco16
5:36am September 24th 2016 via Hootsuite
Turner: Looked at setting of treatment and aromatase inh (AI) - by itself or with adjuvant, found diff in ESR1 mut in ctDNA #MAPonco16
5:35am September 24th 2016 via Hootsuite
Turner: Shows data on ESR1 in ctDNA '15 STM https://t.co/Lsg6w8AGxE #MAPonco16
5:31am September 24th 2016 via Hootsuite
Health economics: price per life-year is a metric that is a bit - unexpected - to me. https://t.co/QHvn3xLrT9
5:30am September 24th 2016 via Twitter Web Client
Turner: Example where looks like primary tumor: clonal muts come down together, and come up together. RB1 shows up late post-surg #MAPonco16
5:29am September 24th 2016 via Hootsuite
Turner: Shows genes mutated in primary tumor, and ctDNA at 17mo pre-relapse, 8-mos, then met. PIK3CA clearly progresses in ctDNA #MAPonco16
5:28am September 24th 2016 via Hootsuite
Turner: Can high-coverage seq help to determine micro-mets? 273 gene panel, 460x ave depth: shows an extreme example #MAPonco16
5:27am September 24th 2016 via Hootsuite
Turner: Can ctDNA be used to guide Rx? C-TRAK study: randomized + ctDNA, intervention or observation #MAPonco16
5:26am September 24th 2016 via Hootsuite
RT @jsoriamd: Progress in #breastcancer in the UK Nick Turner #MAPonco16 https://t.co/XSwYjrmn9B
5:24am September 24th 2016 via Twitter Web Client
RT @jsoriamd: High proliferative TNBC release more cDNA than other BC #MAPonco16 Turner https://t.co/DnANPjVFkK
Turner: 3 pts with brain-only mets - mutation tracking not detected. Longer followup - >30mos - 100% PPV for relapse (unpubl) #MAPonco16
5:24am September 24th 2016 via Hootsuite
Turner: Lead-time - Median lead time over clinical relapse was 7.9mos. Shows a case where it was 13 mos. #MAPonco16
5:22am September 24th 2016 via Hootsuite
Turner: 69% found in baseline plasma. Showed chart and P-values; post-surgery 19% ctDNA detected had poor DFS. #MAPonco16
5:20am September 24th 2016 via Hootsuite
Turner: Showed PIK3CA, baseline, post-surgery with 7 copies/mL 6mos later to 198, pt relapsed. Other: no relapse, no ctDNA det. #MAPonco16
5:18am September 24th 2016 via Hootsuite
Turner: Study - collected samples prior to neoadjuvant Rx, during and post. Seq of primary br ca, used dPCR for ctDNA to 0.1% #MAPonco16
Turner: #MAPonco16 Starts w/ ctDNA Dawson '14 NEJM https://t.co/G0x8KPlPqQ Shows increased incidence of br ca since '85, but lower mortality
5:15am September 24th 2016 via Hootsuite
Nicolas Turner (ICR) Predicting relapse using ctDNA in breast cancer #MAPonco16
5:13am September 24th 2016 via Hootsuite
Sullivan: One part of the problem is advertising, how PM is presented; journalism, press releases from org's, public view #MAPonco16
5:07am September 24th 2016 via Hootsuite
Sullivan: #MAPonco16 Ref '14 paper, 'War on cancer and the influence of the medical-industrial complex' https://t.co/8WaN3gOVcw
5:01am September 24th 2016 via Hootsuite
Sullivan: Strong countries negotiate price; weak political coherence in public policy doesn't recognize need for HTA mechanisms #MAPonco16
5:00am September 24th 2016 via Hootsuite
Sullivan: PM is adding on costs to systems and societies 'in an unaffordable, unsustainable manner' #MAPonco16
4:57am September 24th 2016 via Hootsuite
Sullivan: Can emerging heath systems afford PM? Fig from BMC Med ref https://t.co/usetgiP1st Cancer dx is potentially disastrous #MAPonco16
4:56am September 24th 2016 via Hootsuite
Sullivan: Shows a Mumbai storefront sign: "House of Diagnostics" and says "I went in, and they are nice people" #MAPonco16
4:54am September 24th 2016 via Hootsuite
Sullivan: Chart per-capita spend against mortality to incidence; there are 'seriously weak health systems in EU' #MAPonco16
4:53am September 24th 2016 via Hootsuite
Sullivan: CAGR of medicines are 11%; but hitting saturation (direct is only 1%) #MAPonco16
4:52am September 24th 2016 via Hootsuite
Sullivan: Chart by country and by type of cancer, it is obvious some countries are 'massively undertreating' #MAPonco16
4:51am September 24th 2016 via Hootsuite
Sullivan: Says CEOs say stock buybacks is a problem as well. Onto cost burden: Lancet https://t.co/89dxl1we8K Many data charts #MAPonco16
4:50am September 24th 2016 via Hootsuite
